Yuxia obtained her PhD from the Chinese Academy of Sciences, followed with post-doctoral training in cell signaling and immunology at University of Cambridge (UK) and Walter and Eliza Hall Institute of Medical Research (Australia). During her postdoc training, Yuxia has made major contributions in describing a number of immune checkpoint regulators, including CD52-Siglec10, FOXP3-TIGIT, and EZH2/SUZ12, which have now served as drug targets for autoimmune diseases and cancer.

Yuxia was appointed Principal Investigator in April 2016 at Guangzhou Women and Children’s Medical center, Guangzhou Medical University. Her lab utilizes multiple discipline approaches studying debilitating and chronic diseases that affect the normal function of the digestive system in infants and children. These studies have led to novel diagnosis and treatment for biliary atresia and inflammatory bowel diseases. Based on the success of these bench-to-bed studies, her lab is currently building a pediatric disease atlas. They also explore pathomechanisms of novel risk or disease candidate genes that may lead to brand new therapies for immune related disorders.